- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Fine-Tuning Your Multichannel Marketing Strategy
In today’s pharmaceutical industry, it seems there are nearly as many communication channels as there are instruments in the Philharmonic.
In today’s pharmaceutical industry, it seems there are nearly as many communication channels as there are instruments in the Philharmonic, and a similar level of coordination is needed to ensure multichannel success.
Then, there’s the added challenge of managing interactions with today’s multifaceted customer, who could be a government agent; payer; physician (primary, specialist, or key opinion leader); nurse; hospital administrator; or Considering all the complexity in today’s life sciences industry, hitting the right note is much more difficult than just communicating through all channels. It requires a tremendous amount of coordination between sales, marketing and medical affairs.
In this article, Jan van den Burg looks at what companies need to do to execute a multichannel strategy that’s always in tune with the customer.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
